OSTX

OS Therapies Incorporated · AMEX

Sector Health Technology
Industry Biotechnology
Website -
Employees(FY) -
ISIN US68764Y2072

Performance

-12.78%

+5.37%

-7.65%

-15.46%

-63.32%

YTD

-37.45%

Profile

Advanced Technical Analysis

Technical Analysis of OSTX 2025-05-22

The stock indicators suggest a bearish sentiment overall, with a Moving Average Score of 0 indicating strong downward pressure, while the Oscillators Score of 45 remains neutral, and the Technical Score of 22 reinforces the bearish outlook. This combination implies a lack of bullish momentum and potential challenges for upward price movement in ...

Technical Scores and Rating

Moving Average Score

Oscillator Score

Technical Rating

Stock Analysis of OSTX

Stock Rank

Recent News & Updates

2025-05-15 18:00
OS Therapies Reports First Quarter 2025 Financial Results and Provides Business Update(Yahoo Finance)
2025-05-14 18:00
OS Therapies Forms Subsidiary OS Animal Health to Commercialize OST-HER2 for Canine Osteosarcoma(Yahoo Finance)
2025-05-06 20:45
OS Therapies Announces Issuance of U.S. Patent #12,239,738 Protecting Commercial Manufacturing Market Exclusivity for OST-HER2 in Rare Pediatric Cancer Osteosarcoma and Full Listeria Cancer Immunotherapy Platform into 2040(Yahoo Finance)
2025-05-01 21:32
Emmy-Winning Series Debuts Trailer for "Shelter Me: The Cancer Pioneers" Offering A Hopeful Look at Breakthrough Cancer Therapies(Yahoo Finance)
2025-04-21 19:40
OS Therapies FDA Meeting Request Granted(Yahoo Finance)
2025-04-13 22:15
With Young Adult Cancer on the Rise, New Therapies Spark Investor Buzz(Prnewswire)
2025-04-09 19:42
OS Therapies Announces Positive Data for OST-HER2 in the Treatment of Unresected Osteosarcoma in Dogs Opening the Potential for Use as Front-Line Therapy in Humans(Yahoo Finance)
2025-04-08 19:40
OS Therapies Completes Acquisition of Advaxis Immunotherapies Clinical, Pre-clinical and IP Assets from Ayala Pharmaceuticals(Yahoo Finance)
2025-04-06 18:00
OS Therapies Requests Meeting with FDA to Gain Agreement on Surrogate Endpoint(s) for Breakthrough Therapy Designation & Accelerated Approval of OST-HER2 in the Prevention of Recurrence of Fully Resected, Lung Metastatic Osteosarcoma(Yahoo Finance)
2025-04-01 19:40
OS Therapies to Host Analyst Day at NYSE on April 7, 2025(Yahoo Finance)
2025-03-31 04:30
OS Therapies Reports Full Year 2024 Financial Results and Provides Business Update(Yahoo Finance)
2025-03-30 19:40
OS Therapies Provides Regulatory Update on Rare Pediatric Cancer Immunotherapy Candidate OST-HER2 for Human Osteosarcoma(Yahoo Finance)
2025-03-24 19:40
OS Therapies OST-HER2 Immunotherapy for Osteosarcoma Featured in Upcoming Movie Shelter Me: The Cancer Pioneers(Yahoo Finance)
2025-03-22 20:49
OS Therapies (OSTX): Among the Penny Stocks With Huge Upside Potential According to Analysts(Insidermonkey)
2025-03-20 19:40
OS Therapies to Attend The Jones Healthcare and Technology Innovation Conference(Yahoo Finance)
2025-03-12 19:40
OS Therapies Awarded OST-HER2 Clinical Trial Data Presentation at MIB Agents FACTOR Osteosarcoma Conference(Yahoo Finance)
2025-03-10 19:40
OS Therapies Schedules United Kingdoms Medicines and Healthcare products Regulatory Agency's (MHRA) Scientific Advice Meeting in the Third Quarter of 2025 for Review of its OST-HER2 Immunotherapy Candidate for Osteosarcoma(Yahoo Finance)
2025-02-27 20:00
Calidi Biotherapeutics and OS Therapies Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV(Yahoo Finance)
2025-02-26 03:01
Join OS Therapies Exclusive Live Investor Webinar and Q&A Session on February 27(Yahoo Finance)
2025-02-23 18:25
OS Therapies Forms Subsidiary OS Drug Conjugates and Initiates Review of Strategic Options for its tunable ADC & Drug Conjugates Platforms(Yahoo Finance)
2025-02-19 16:00
OS Therapies Receives Patent Notice of Allowance from U.S. Patent & Trademark Office Covering Commercial Manufacturing of OST-HER2(Yahoo Finance)
2025-02-14 00:51
Small-Cap OS Therapies Inks Commercial Manufacture Agreements For Lead Cancer Drug For Rare Type Of Bone Cancer(Yahoo Finance)
2025-02-13 18:36
OS Therapies Initiates Commercial-ready Manufacturing of OST-HER2 to Support Anticipated Biologics Licensing Authorization (BLA) Filing(Yahoo Finance)
2025-02-03 18:33
OS Therapies Provides Corporate Update(Yahoo Finance)
2025-02-02 19:30
RedChip Launches RedChat: Revolutionary AI Chatbot for Small-Cap Stock Analysis(Yahoo Finance)
2025-01-29 20:35
OS Therapies to acquire listeria programs from Ayala Pharmaceuticals(Yahoo Finance)
2025-01-28 21:05
OS Therapies Agrees to Acquire All Listeria Monotygenes-based Immuno-Oncology Programs and IP Assets from Ayala Pharmaceuticals, Adding Phase 2 Lung Cancer and Phase 1 Prostate Cancer Programs to Pipeline(Yahoo Finance)
2025-01-16 19:35
OS Therapies price target raised to $15 from $8 at Maxim(Yahoo Finance)
2025-01-14 18:40
OS Therapies Announces Phase 2b Clinical Trial of OST-HER2 Achieves Primary Endpoint with Statistical Significance in the Prevention of Recurrent, Fully Resected, Lung Metastatic Osteosarcoma(Yahoo Finance)
2025-01-01 22:16
OS Therapies to Attend the 43rd Annual J.P. Morgan Healthcare Conference(Yahoo Finance)

Page 1 of 1

previousnext

Disclaimer: The information provided here and on kavout.com is for general informational purposes only. It does not constitute investment advice, financial advice, trading advice, or any other sort of advice. Kavout makes no recommendations regarding investment decisions based on this information. You are solely responsible for your investments. Please conduct your own research and consult qualified financial advisors before investing. Past performance does not guarantee future results.

OSTX

Performance

Profile

Technical Analysis of OSTX 2025-05-22

Stock Analysis of OSTX

Recent News & Updates

Notifications

Upgrade to Pro

Pro Features Include: